Olema Oncology, Inc. has filed an 8-K report with the Securities and Exchange Commission announcing a change in its corporate name, effective November 12, 2026. The company, formerly known as Olema Pharmaceuticals, Inc., has officially changed its name to Olema Oncology, Inc. The change was effected by filing an Eighth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware.
The filing indicates that the name change became effective at 4:01 p.m., Eastern Time, on November 12, 2026. According to the Delaware General Corporation Law, stockholder approval was not required to effect this name change. Concurrently, the company’s Board of Directors approved an amendment and restatement of the Amended and Restated Bylaws to reflect the new corporate identity.
The company’s common stock will continue to trade on The Nasdaq Global Select Market under the existing ticker symbol “OLMA.”
In other business updates, Olema Oncology reported that its principal executive offices have relocated from 780 Brannan Street in San Francisco to 365 Oyster Point Blvd., Suite 400, in South San Francisco, effective November 12, 2026.
